Zevra Therapeutics Inc (ZVRA) USD0.0001

Sell:$9.73Buy:$9.76$0.33 (3.51%)

NASDAQ:1.02%
Market closed | Prices delayed by at least 15 minutes
Sell:$9.73
Buy:$9.76
Change:$0.33 (3.51%)
Market closed | Prices delayed by at least 15 minutes
Sell:$9.73
Buy:$9.76
Change:$0.33 (3.51%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Key people

Neil F. Mcfarlane
President, Chief Executive Officer, Director
R. LaDuane Clifton
Chief Financial Officer, Treasurer
Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Rahsaan W. Thompson
Chief Legal Officer, Secretary, Compliance Officer
Adrian Quartel
Chief Medical Officer
Tamara A. Favorito
Independent Chairman of the Board
Thomas D. Anderson
Independent Director
John B. Bode
Independent Director
Douglas W. Calder
Independent Director
Wendy L. Dixon
Independent Director
Click to see more

Key facts

  • EPIC
    ZVRA
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US4884452065
  • Market cap
    $514.54m
  • Employees
    59
  • Shares in issue
    56.26m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.